Read More

Citi Monitors Competitive Threats To Eli Lilly, Says It Is Positioned To Maintain Leadership And Expand

Citi Research raises price target for Eli Lilly, citing improved risk-adjusted sales outlook for GLP-1 agonist orforglipron. With Phase 3 trials ongoing since 2023, concerns about liver toxicity diminish. Analysts foresee potential sales surpassing $85 billion, closely watching competitive landscape.

LLY